

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)

2. (Cancelled).

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Currently Amended) A medical device comprising:
an implantable structure;

trichostatin A, in thereapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury, the trichostatin A being incorporated into a basecoat polymeric material, the concentration of trichostatin A being less than 100 nano molar;

rapamycin, in therapeutic dosages, releasably affixed to the implantable structure for the treatment of restenosis following vascular injury, the rapamycin being incorporated into the basecoat polymeric material the rapamycin and the trichostatin A potentiating each others effectiveness; and

a topcoat polymeric material affixed to the basecoat polymeric material to control the elution rate of the and the rapamycin, the

topcoat polymeric material and the basecoat polymeric material being immiscible polymeric materials, wherein the basecoat polymeric material includes a copolymer polyvinylidene fluoride-co-hexafluoropropylene with a sixty/forty weight ratio of VDF:HFP and the topcoat comprises a four hundred ninety microgram ~~BMA~~ poly(n-butylmethacrylate) layer, wherein the basecoat and the topcoat are mixed and precipitated from solution to create a phase separation of two distinct layers.

7. (Original) The medical device according to Claim 6, wherein the implantable structure comprises a stent.

8. (Original) The medical device according to Claim 6, wherein the implantable structure comprises a stent-graft.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)